GlassScriptPhysician profile
Erin Joyce Perkins
NPI 1043877426
$2,149.82
in general payments reported to CMS, 2019-2025
27 companies · $425 in 2025
The $425 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $237 · 2022: $431 · 2023: $487 · 2024: $448 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $355.24 | 2019-2023 | Floseal |
| Pacira Pharmaceuticals Incorporated | $257.87 | 2021-2022 | |
| Sage Therapeutics, LLC | $213.92 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $164.59 | 2023-2024 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Davol INC. | $162.15 | 2022 | |
| Astellas Pharma US INC | $151.87 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $129.43 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $89.16 | 2024-2025 | Fluent Fluid Management System, Novasure, Thinprep 2000 Processor |
| Medtronic, INC. | $72.36 | 2023-2025 | Truclear |
| Myriad Women'S Health, INC. | $71.48 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $51.86 | 2021-2023 | |
| Smith+Nephew, INC. | $51.42 | 2021 | |
| Organon LLC | $47.62 | 2024-2025 | Nexplanon |
| Millicent US INC | $35.14 | 2023-2024 | Intrarosa, Femring |
| Gynesonics, INC. | $33.35 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $33.03 | 2024-2025 | Slynd |
| Cumberland Pharmaceuticals, INC. | $30.27 | 2024-2025 | Caldolor |
| Evofem Biosciences, INC. | $25.02 | 2023-2025 | Phexxi, Solosec, Phexx |
| Supernus Pharmaceuticals, INC. | $24.26 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $21.32 | 2021 | |
| Glaxosmithkline, LLC. | $20.32 | 2022 | |
| Dexcom, INC. | $19.68 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $19.11 | 2024 | |
| Aspira Women'S Health INC | $18.92 | 2024 | Ova1 |
| Optumhealth Care Solutions, LLC | $18.59 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Pfizer INC. | $17.54 | 2023 | |
| Medical Device Business Services, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.